Management updated its financial outlook for fiscal year 2019, and the news wasn't pretty. The company stated that generic drug market conditions haven't been as favorable as it had initially predicted back in April. As a result, the company now believes that its financial targets are off by about $80 million. Based on this updated information, management shared the following financial guidance with investors:
- Adjusted EBIDTA is expected to land between $540 million and $590 million. This is well below the previously discussed range of $615 million to $675 million.
- Net loss is expected to land between $125 million and $175 million. This is also considerably worse than the prior guidance of a net loss between $40 million and $95 million.
- Adjusted net loss per share is projected to land between $(0.04) and break even. This is also down from its prior outlook of earnings of $0.02 to $0.06.
- Sales, same-store sales, and capital expenditures guidance remain unchanged.
Importantly, this updated guidance will not have any impact on its proposed merger with Albertsons .
Given the negative financial adjustments, it isn't hard to figure out why shares are cratering today.
Today's financial update should serve as even more proof that Rite Aid needs to do something -- anything -- to find a way to right its ship. My Foolish colleague Rick Munarriz pointed out that merging with Albertsons makes a lot of sense, even if that view isn't universally praised by Wall Street. The combined entity would certainly command more bargaining power with suppliers, which could go a long way toward helping it compete against giants like CVS Health , Walgreens Boots Alliance , and , increasingly , Amazon .
The shareholder vote to approve the merger is set for Aug. 9, so investors won't have to wait long to find out what's happening next. Given today's financial update, it's hard to be optimistic about this company's chances of competing over the long term if the merger fails to materialize.
10 stocks we like better than Rite Aid
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Rite Aid wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Brian Feroldi owns shares of Amazon. The Motley Fool owns shares of and recommends Amazon. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.